Form 8-K - Current report:
SEC Accession No. 0001193125-25-192794
Filing Date
2025-08-29
Accepted
2025-08-29 16:18:38
Documents
19
Period of Report
2025-08-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d945054d8k.htm   iXBRL 8-K 35380
2 EX-4.1 d945054dex41.htm EX-4.1 620211
6 GRAPHIC g945054g0828232916762.jpg GRAPHIC 1937
7 GRAPHIC g945054g0828232917035.jpg GRAPHIC 2380
8 GRAPHIC g945054g0828232917252.jpg GRAPHIC 2373
9 GRAPHIC g945054g0828232917453.jpg GRAPHIC 2380
10 GRAPHIC g945054g0828232917641.jpg GRAPHIC 2021
11 GRAPHIC g945054g0828232917886.jpg GRAPHIC 2786
  Complete submission text file 0001193125-25-192794.txt   923183

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA srpt-20250828.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE srpt-20250828_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srpt-20250828_pre.xml EX-101.PRE 10811
21 EXTRACTED XBRL INSTANCE DOCUMENT d945054d8k_htm.xml XML 3503
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14895 | Film No.: 251281148
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)